1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 34 pages

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Integrated BioTherapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Integrated BioTherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Integrated BioTherapeutics, Inc.
- The report provides overview of Integrated BioTherapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Integrated BioTherapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Integrated BioTherapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Integrated BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Integrated BioTherapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrated BioTherapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Integrated BioTherapeutics, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Integrated BioTherapeutics, Inc. Snapshot 5
Integrated BioTherapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Integrated BioTherapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Integrated BioTherapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Integrated BioTherapeutics, Inc. - Pipeline Products Glance 11
Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Integrated BioTherapeutics, Inc. - Drug Profiles 14
STEBVax 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
(Ebola + Marburg) vaccine 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Antibodies for Ebola and Marburg Viral Infections 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
AT-62aa 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Monoclonal Antibodies for Ebola and Marburg Infections 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibodies for Equine Encephalitis and Chikungunya 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Monoclonal Antibody 1 for Staphylococcus Aureus Infections 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Integrated BioTherapeutics, Inc. - Pipeline Analysis 26
Integrated BioTherapeutics, Inc. - Pipeline Products by Target 26
Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration 27
Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type 28
Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 29
Integrated BioTherapeutics, Inc. - Recent Pipeline Updates 30
Integrated BioTherapeutics, Inc. - Dormant Projects 31
Integrated BioTherapeutics, Inc. - Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Integrated BioTherapeutics, Inc., Key Information 5
Integrated BioTherapeutics, Inc., Key Facts 5
Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016 7
Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016 8
Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016 9
Integrated BioTherapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016 10
Integrated BioTherapeutics, Inc. - Phase I, 2016 11
Integrated BioTherapeutics, Inc. - Preclinical, 2016 12
Integrated BioTherapeutics, Inc. - Discovery, 2016 13
Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016 26
Integrated BioTherapeutics, Inc. - Pipeline by Route of Administration, 2016 27
Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016 28
Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 29
Integrated BioTherapeutics, Inc. - Recent Pipeline Updates, 2016 30
Integrated BioTherapeutics, Inc. - Dormant Developmental Projects,2016 31

List of Figures
Integrated BioTherapeutics, Inc. - Pipeline by Indication, 2016 7
Integrated BioTherapeutics, Inc. - Pipeline by Stage of Development, 2016 8
Integrated BioTherapeutics, Inc. - Monotherapy Products in Pipeline, 2016 9
Integrated BioTherapeutics, Inc. - Pipeline by Target, 2016 26
Integrated BioTherapeutics, Inc. - Pipeline by Molecule Type, 2016 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Protalix BioTherapeutics, Inc. (PLX) - Financial and Strategic SWOT Analysis Review

Protalix BioTherapeutics, Inc. (PLX) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Protalix BioTherapeutics, Inc. (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company provides elelyso, a plant cell-expressed ...

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • September 2016
  • by Global Data

Summary Oxford BioTherapeutics Ltd (Oxford BioTherapeutics) is a biotechnology company that focuses on the development antibody drug conjugates (ACDs) for the treatment of wide variety of cancers. The ...

Northwest Biotherapeutics, Inc. (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Northwest Biotherapeutics, Inc. (NWBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • August 2016
  • by Global Data

Summary Northwest Biotherapeutics, Inc. (NW Bio) is a development stage biotechnology company. It discovers and develops immunotherapy products to treat cancer in an effective way without toxicities associated ...

Eleven Biotherapeutics Inc

November 2016 $ 87

Northwest Biotherapeutics, Inc.

November 2016 $ 87

Asterias Biotherapeutics Inc

November 2016 $ 87

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.